| Name | Azintuxizumab |
|---|
| Description | Azintuxizumab (ABBV-383; PR-1471272) is a SLAMF7 targeting antibody-drug conjugate (ADC). Azintuxizumab consists of a SLAMF7-targeted mAb and a monomethyl auristatin E (MMAE) via a cathepsin B-cleavable peptide linker. Azintuxizumab has the potential for the research of multiple myeloma[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |